Skip to main content
logo
Castle Biosciences, Inc. (CSTL)
NASDAQ: CSTL · Real-Time Price · USD
26.48
+2.02 (8.26%)
Jul 30, 2026, 3:36 PM EDT - Market open

Castle Biosciences Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
339.92344.23332.07219.79137.0494.09
Revenue Growth
-2.06%3.66%51.09%60.38%45.65%50.18%
Gross Profit
264.74273.2271.86174.81105.0378.26
Operating Income
-33.29-42.818.67-67.98-72.86-40.08
Net Income
-22.51-24.318.25-57.47-67.14-48.73
Earnings Per Share
-0.44-0.830.62-2.14-2.58-1.24
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
261.69299.51293.13243.1258.63329.63
Total Debt
36.7236.9126.3415.3413.318.08
Net Cash (Debt)
224.96262.59266.79227.76245.32321.55
Net Cash Growth
-9.77%-1.57%17.13%-7.15%-23.71%-20.95%
Net Cash Per Share
7.649.069.128.509.4212.79

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
48.2564.3564.87-5.63-41.66-18.98
Capital Expenditures
-43.74-36.02-28.33-13.62-5.63-3.48
Free Cash Flow
4.5228.3336.54-19.25-47.29-22.47
Free Cash Flow Growth
-89.18%-22.48%----

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
77.88%79.37%81.87%79.53%76.64%83.18%
Operating Margin
-9.79%-12.44%2.61%-30.93%-53.16%-42.60%
Pretax Margin
-5.25%-8.62%6.49%-26.10%-50.28%-42.53%
Profit Margin
-6.62%-7.06%5.49%-26.15%-48.99%-51.80%
FCF Margin
1.33%8.23%11.00%-8.76%-34.51%-23.88%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
--42.98---
P/FCF Ratio
174.0040.7720.77---
PS Ratio
2.313.352.292.694.5611.56